A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.

Status:	Completed
Conditions:	Fibromyalgia, Pain
Therapuetic Areas:	Musculoskeletal, Rheumatology
Healthy:	No
Age Range:	18 - 65
Updated:	12/6/2018
Start Date:	August 2008
End Date:	June 2009

A Phase 2 Randomized Double-Blind Placebo-Controlled Crossover Study Assessing The Ability Of Esreboxetine (PNU-165442g) To Improve Cognitive Function In Fibromyalgia Patients.

The study is designed to assess if esreboxetine can improve the cognitive function of
patients with fibromyalgia. Cognitive function is defined as the ability to concentrate,
remember things and make decisions or problem solve. The study is also designed to assess if
there is a difference in cognitive function between fibromyalgia patients and matched control
subjects.

Inclusion Criteria:

- Subjects who have a recognised diagnosis of fibromyalgia, with defined minimum pain
criteria. Control subjects must not have a fibromyalgia diagnosis or symptoms and must
match fibromyalgia subjects for age, length of education and gender

Exclusion Criteria:

- Other confounding pain, cognitive disease or impairment, disease that could put the
subject at risk or subjects who are on prohibited medications that cannot be washed
out.

- Any subjects with a diagnosis of certain psychiatric disorders in particular major
depression or suicidal risk. Matched control subjects have similar exclusions.

We found this trial at

sites

Pfizer Investigational Site

Oklahoma City, Oklahoma 73112

from

Oklahoma City, OK